| Title: | Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life |
| Journal: | Nature Communications |
| Published: | 27 Jul 2022 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/35896539/ |
| DOI: | https://doi.org/10.1038/s41467-022-31655-z |
| URL: | https://www.nature.com/articles/s41467-022-31655-z.pdf |
| Citations: | 13 (11 in last 2 years) as of 8 Aug 2024 |
Publication 10375
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Obesity is a pre-disposing condition for chronic obstructive pulmonary disease, asthma, and pulmonary arterial hypertension. Accumulating evidence suggests that metabolic influences during development can determine chronic lung diseases (CLD). We demonstrate that maternal obesity causes early metabolic disorder in the offspring. Here, interleukin-6 induced bronchial and microvascular smooth muscle cell (SMC) hyperproliferation and increased airway and pulmonary vascular resistance. The key anti-proliferative transcription factor FoxO1 was inactivated via nuclear exclusion. These findings were confirmed using primary SMC treated with interleukin-6 and pharmacological FoxO1 inhibition as well as genetic FoxO1 ablation and constitutive activation. In vivo, we reproduced the structural and functional alterations in offspring of obese dams via the SMC-specific ablation of FoxO1. The reconstitution of FoxO1 using IL-6-deficient mice and pharmacological treatment did not protect against metabolic disorder but prevented SMC hyperproliferation. In human observational studies, childhood obesity was associated with reduced forced expiratory volume in 1 s/forced vital capacity ratio Z-score (used as proxy for lung function) and asthma. We conclude that the interleukin-6-FoxO1 pathway in SMC is a molecular mechanism by which perinatal obesity programs the bronchial and vascular structure and function, thereby driving CLD development. Thus, FoxO1 reconstitution provides a potential therapeutic option for preventing this metabolic programming of CLD.</p>
26 Authors
- Jaco Selle
- Katharina Dinger
- Vanessa Jentgen
- Daniela Zanetti
- Johannes Will
- Theodoros Georgomanolis
- Christina Vohlen
- Rebecca Wilke
- Baktybek Kojonazarov
- Oleksiy Klymenko
- Jasmine Mohr
- Silke v. Koningsbruggen-Rietschel
- Christopher J. Rhodes
- Anna Ulrich
- Dharmesh Hirani
- Tim Nestler
- Margarete Odenthal
- Esther Mahabir
- Sreenath Nayakanti
- Swati Dabral
- Thomas Wunderlich
- James Priest
- Werner Seeger
- Jörg Dötsch
- Soni S. Pullamsetti
- Miguel A. Alejandre Alcazar
1 Application
| Application ID | Title |
|---|---|
| 13721 | Causal associations of circulating biomarkers with cardiovascular disease |
Enabling scientific discoveries that improve human health